Трансплантационные технологии для лечения нарушений углеводного обмена
Аннотация
В обзор включены результаты ретроспективных и проспективных клинических зарубежных и отечественных исследований и рекомендаций по проблеме применения трансплантационных технологий для лечения сахарного диабета I типа и панкреатогенного диабета при хроническом панкреатите и панкреатопривных состояниях. Изложены современные данные о распространенности сахарного диабета и современных методах инсулинотерапии. Рассмотрены результаты трансплантации поджелудочной железы и островков Лангерганса при первичных инсулинозависимых состояниях. Представлен анализ технологии выделения и аутотрансплантации островков после панкреатэктомии при хроническом панкреатите и доброкачественных (опухолевых) заболеваниях.
Об авторах
В. Е. Загайнов
ФГБУ ВО «Приволжский исследовательский медицинский университет» Минздрава России;
ФБУЗ «Приволжский окружной медицинский центр ФМБА России»
Россия
Россия
Загайнов Владимир Евгеньевич.
603109, Нижний Новгород, ул. Ильинская,14.
А. В. Мелешина
ФГБУ ВО «Приволжский исследовательский медицинский университет» Минздрава России
Россия
Нижний Новгород
Россия
Нижний Новгород
К. Г. Корнева
ФГБУ ВО «Приволжский исследовательский медицинский университет» Минздрава России;
ГБУЗ Нижегородской области «Городская клиническая больница № 13 Нижнего Новгорода
Россия
Нижний Новгород
Россия
Нижний Новгород
С. А. Васенин
ФБУЗ «Приволжский окружной медицинский центр ФМБА России»
Россия
Нижний Новгород
Россия
Нижний Новгород
Е. В. Загайнова
ФГБУ ВО «Приволжский исследовательский медицинский университет» Минздрава России
Россия
Нижний Новгород
Россия
Нижний Новгород
Список литературы
1. Шестакова МВ, Викулова ОК, Железнякова АВ, Исаков МА, Дедов ИИ. Эпидемиология сахарного диабета в Российской Федерации: что изменилось за последнее десятилетие? Терапевтический архив. 2019; 10: 4–13.
2. Patterson C, Guariguata L, Dahlquist G et al. Diabetes in the young – a global view and worldwide estimates of numbers of children with type 1 diabetes. Diabetes research and clinical practice. 2014; 103: 161–175.
3. Дедов ИИ, Шестакова МВ, Викулова ОК. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017; 20 (1): 13–41.
4. Дедов ИИ, Омельяновский ВВ, Шестакова МВ и др. Сахарный диабет как экономическая проблема в Российской Федерации. Сахарный диабет. 2016; 19 (1): 30–43.
5. Aghazadeh Y, Nostro MC. Cell Therapy for Type 1 Diabetes: Current and Future Strategies. Curr Diab Rep. 2017; 17: 37.
6. Gruessner AC, Gruessner RW. Pancreas transplantation for patients with type 1 and type 2 diabetes mellitus in the United States: a registry report. Gastroenterol Clin North Am. 2018; 47 (2): 417–441.
7. Шумаков ВИ, Игнатенко СН, Петров ГН и др. Трансплантация почки и поджелудочной железы больным инсулинозависимым сахарным диабетом. Хирургия. 1991; 7: 3–8.
8. Готье СВ. Трансплантация дистального фрагмента поджелудочной железы от родственного донора. Вестник трансплантологии и искусственных органов. 2005; 3: 30–31.
9. Готье СВ, Азуманов СВ. Трансплантация поджелудочной железы в лечении пациентов с сахарным диабетом 1-го типа: технические аспекты ее выполнения. Вестник трансплантологии и искусственных органов. 2017; 19 (3): 70–80.
10. Kandaswamy R, Stock PG, Gustafson SK et al. OPTN/ SRTR 2016 Annual data report: Pancreas. Am J Transplant. 2018; 18 (Suppl. 1): 114–171.
11. Gruessner AC, Laftavi MR, Pankewycz O et al. Simultaneous pancreas and kidney transplantation – is it a treatment option for patients with type 2 diabetes mellitus? An analysis of the international pancreas transplant registry. Curr Diab Rep. 2017; 17 (6): 44.
12. Dean PG, Kukla A, Stegall MD et al. Pancreas transplantation. BMJ. 2017; 357: 1321.
13. Gruessner AC, Gruessner RW. Pancreas transplantation for patients with type 1 and type 2 diabetes mellitus in the United States: a registry report. Gastroenterol Clin North Am. 2018; 47 (2): 417–441.
14. Lombardo C, Perrone VG, Amorese G et al. Update on pancreatic transplantation on the management of diabetes. Minerva Med. 2017; 108 (5): 405–418.
15. Dholakia S, Mittal S, Quiroga I et al. Pancreas transplantation: past, present, future. Am J Med. 2016; 129 (7): 667–673.
16. Niederhaus SV. Pancreas transplant alone. Curr Opin Organ Transpl. 2015; 20 (1): 115–120.
17. Drewitz P, Loss M, Loss J, Apfelbacher CJ. Predictors of non-transplantation of adult donor organs – an observational study using routine data from Eurotransplant. BMC Health Services Research. 2014; 14: 584.
18. Antonioli B, Galuzzi M. Islet transplantation 30 years after the first transplants. Semin Pediatr Surg. 2014; 23 (2): 83–90.
19. Shapiro AJ, Lakey JT et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid- free immunosuppressive regimen. N Engl J Med. 2000; 343 (4): 230–238.
20. Hering BJ, Clarke WR, Bridges ND et al. Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia. Diabetes Care. 2016; 39: 1230–1240.
21. Gill RG, Bishop NH. Clinical islet transplantation: where immunity and metabolism intersect? Curr Opin Endocrinol Diabetes Obes. 2012; 19 (4): 249–254.
22. Яковец НМ, Назарова ЕА, Кривенко СИ и др. Первый опыт выделения островковых комплексов поджелудочной железы человека для аллогенной трансплантации при сахарном диабете 1-го типа. Медицинский журнал. 2013; 4: 119–122.
23. Rheinheimer J, Bauer AC, Silveiro SP et al. Human pancreatic islet transplantation: an update and description of the establishment of a pancreatic islet isolation laboratory. Arch Endocrinol Metab. 2015; 59 (2): 161–70.
24. Gamble A, Pepper AR, Bruni A, Shapiro AM. The journey of islet cell transplantation and future development. Islets. 2018; 10 (2): 80–94.
25. Liu Y, Song B, Ran X et al. Molecular imaging of pancreatic islet transplantation. Exp Clin Endocrinol Diabetes. 2014; 122 (2): 79–86.
26. Eriksson O, Selvaraju R, Eich T et al. Positron emission tomography to assess the outcome of intraportal islet transplantation. Diabetes. 2016; 65 (9): 2482–2489.
27. Delaune V, Berney T, Lacotte S, Toso C. Intraportal islet transplantation: the impact of the liver microenvironment. Transpl Int. 2017; 30 (3): 227–238.
28. Citro A, Cantarelli E, Pellegrini S et al. Anti-Inflammatory Strategies in Intrahepatic Islet Transplantation. Transplantation. 2018; 2 (240): 102.
29. Ramnath RD, Maillard E, Jones K et al. In vitro assessment of human islet vulnerability to instant bloodmediated inflammatory reaction (IBMIR) and its use to demonstrate a beneficial effect of tissue culture. Cell Transplant. 2015; 24 (12): 2505–2512.
30. Citro A, Cantarelli E, Piemonti L. Anti-inflammatory strategies to enhance islet engraftment and survival. Curr Diab Rep. 2013; 13 (5): 733–744.
31. Naziruddin B, Iwahashi S, Kanak MA et al. Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation. Am J Transplant. 2014; 14: 428–437.
32. Wang S, Zhao Z, Cong Z, Suo G. Thrombin-activatable fibrinolysis inhibitor is activated in an instant blood-mediated inflammatory reaction after intraportal islet transplant. Exp Clin Transplant. 2014; 12 (1): 62–66.
33. Abecassis A, Schuster R, Shahaf G et al. α1-antitrypsin increases interleukin-1 receptor antagonist production during pancreatic islet graft transplantation. Cell Mol Immunol. 2014; 11: 377–386.
34. Markmann JF. Isolated pancreatic islet transplantation: a coming of age. Am J Transplant. 2016; 16 (2): 381–382.
35. Xiao X, Fischbach S, Song Z et al. Transient suppression of TGFβ receptor signaling facilitates human islet transplantation. Endocrinology. 2016; 157 (4): 1348–1356.
36. Itoh T, Nitta T, Nishinakamura H; Kojima D et al. HMGB1-Mediated Early Loss of Transplanted Islets Is Prevented by Anti-IL-6R Antibody in Mice. Pancreas. 2015; 44: 166–171.
37. Monti P, Vignali D, Piemonti L. Monitoring inflammation, humoral and cell-mediated immunity in pancreas and islet transplants. Curr Diabetes Rev. 2015; 11 (3): 135–143.
38. Balamurugan AN, Naziruddin, B, Lockridge, A et al. Islet product characteristics and factors related to successful human islet transplantation from the Collaborative Islet Transplant Registry (CITR) 1999–2010. Am J Transplant. 2014; 14: 2595–2606.
39. Cantarelli E, Citro A, Pellegrini S et al. Transplant Site Influences the Immune Response After Islet Transplantation: Bone Marrow Versus Liver. Transplantation. 2017; 101: 1046–1055.
40. Phelps EA, Headen DM, Taylor WR et al. Vasculogenic bio-synthetic hydrogel for enhancement of pancreatic islet engraftment and function in type 1 diabetes. Biomaterials. 2013; 34 (19): 4602–4611.
41. Scavini M, Dudnani E, Pasquale V et al. Diabetes after pancreatic surgery: novel issues. Curr Diab Rep. 15 (4) 2015.
42. Parsaik A, Murad M, Sathananthan F et al. Metabolic and target organ outcomes after total pancreatectomy: Mayo Clinic experience and meta-analysis of the literature. Clin Endocrinol. 2010 Dec; 73 (6): 723–731.
43. Renaud F, Chetboun M, Thevenet J. Safety of Islet Autotransplantation After Pancreatectomy for Adenocarcinoma. Transplantation. 2019 Jan; 103 (1): 177–181.
44. Trikudanathan G, Navaneethan U, Vege SS. Modern treatment of patients with chronic pancreatitis. Gastroenterol Clin North Am. 2012; 41 (1): 63–76.
45. Chinnakotla S, Beilman GJ, Dunn TB et al. Factors predicting outcomes after a total pancreatectomy and islet autotransplantation. Lessons learned from over 500 cases. Ann Surg. 2015; 262 (4): 610–622.
46. Bellin MD, Freeman ML, Gelrud A et al. Total pancreatectomy and islet autotransplantation in chronic pancreatitis: recommendations from Pancreas Fest. Pancreatology. 2014; 14 (1): 27–35.
47. Yadav D, Timmons L, Benson JT et al. Incidence, prevalence and survival of chronic pancreatitis: a populationbased study. Am J Gastroenterol. 2011; 106: 2192–2199.
48. Загайнов ВЕ, Евтихов РМ и др. Хронический осложненный панкреатит. 2012.
49. Muniraj T, Aslanian HR, Farrell J et al. Chronic pancreatitis, a comprehensive review and update. Part I: epidemiology, etiology, risk factors, genetics, pathophysiology, and clinical features. Disease-a-month. 2014; 60: 530–550.
50. Braganza JM, Lee SH, McCloy RF, McMahon MJ. Chronic pancreatitis. Lancet. 2011; 377 (9772): 1184–1197.
51. Mullady DK, Yadav D, Amann ST, O’Connell MR, Barmada MM, Elta GH et al. Type of pain, pain-associated complications, quality of life, disability and resource utilization in chronic pancreatitis: a prospective cohort study. Gut. 2011; 60: 77–84.
52. Blair R, Burkhart K, Hirose M et al. Laparoscopic total pancreatectomy with islet autotransplantation for chronic pancreatitis. J Vis Surg. 2016; 2: 121–127.
53. Paisley P, Kinsella J. Pharmacological management of pain in chronic pancreatitis. Scottish Medical Journal. 2014; 59 (1): 71–79.
54. Bellin MD, Gelrud A, Arreaza-Rubin G et al. Total pancreatectomy with islet autotransplantation. Ann Surg. 2015; 261 (1): 21–29.
55. Takita M, Lara LF, Naziruddin B et al. Effect of the duration of chronic pancreatitis on pancreas islet yield and metabolic outcome following islet autotransplantation. J Gastrointest Surg. 2015; 19: 1236–1246.
56. Bellin MD, Balamurugan AN, Pruett TL et al. No islets left behind: islet autotransplantation for surgery-induced diabetes. Curr Diab Rep. 2012; 12: 580–586.
57. Witkowski P, Savari O, Matthews JB. Islet autotransplantation and total pancreatectomy. Adv Surg. 2014; 48: 223–233.
58. Savari O, Golab K, Wang LJ et al. Preservation of beta cell function after pancreatic islet autotransplantation: University of Chicago experience. Am Surg. 2015; 81: 421–427.
59. Ali NS, Walsh RM. Total pancreatectomy with islet cell autotransplantation: update and outcomes from major centers. Current Treat Options. Gastroenterology. 2014; 12: 350–358.
60. Fan CJ, Hirose K, Walsh CM et al. Laparoscopic total pancreatectomy with islet autotransplantation and intraoperative islet separation as a treatment for patients with chronic pancreatitis. JAMA Surg. 2017; 152: 550–556.
61. Zureikat AH, Nguyen T, Boone BA et al. Robotic total pancreatectomy with or without autologous islet cell transplantation: replication of an open technique through a minimal access approach. Surg Endosc. 2015; 29: 176–183.
62. Sutherland DE, Radosevich DM, Bellin MD et al. Total pancreatectomy and islet autotransplantation for chronic pancreatitis. J Am Coll Surg. 2012; 214: 409–424.
63. Sato T, Ito K, Tamada T et al. Age-related changes in normal adult pancreas: MR imaging evaluation. Eur J Radiol. 2012; 81: 2093–2098.
64. Pasricha PJ. Unraveling the mystery of pain in chronic pancreatitis. Nat Rev Gastroenterol Hepatol. 2012; 9: 140–151.
65. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011; 152: 2–15.
66. Chinnakotla S, Radosevich DM, Dunn TB et al. Longterm outcomes of total pancreatectomy and islet autotransplantation for hereditary/genetic pancreatitis. J Am Coll Surg. 2014; 218: 530–543.
67. Dunderdale J, McAuliffe JC, McNeal SF et al. Should pancreatectomy with islet cell autotransplantation in patients with chronic alcoholic pancreatitis be abandoned? J Am Coll Surg. 2013; 216: 591–596.
68. Lundberg R, Beilman GJ, Dunn TB et al. Metabolic assessment prior to total pancreatectomy and islet autotransplant: utility, limitations and potential. Am J Transplant. 2013; 13: 2664–2671.
69. Robertson RP, Bogachus LD, Oseid E et al. Assessment of beta-cell mass and alpha- and beta-cell survival and function by arginine stimulation in human autologous islet recipients. Diabetes. 2015; 64 (2): 565–572.
70. Hall TC, Garcea G, Webb MA et al. The socio-economic impact of chronic pancreatitis: a systematic review. J Eval Clin Pract. 2014; 20: 203–207.
71. Garcea G, Pollard CA, Illouz S, Webb M, Metcalfe MS, Dennison AR. Patient satisfaction and cost-effectiveness following total pancreatectomy with islet cell transplantation for chronic pancreatitis. Pancreas. 2013; 42: 322– 328.
72. Rickels MR, Liu C, Shlansky-Goldberg RD et al. Improvement in beta-cell secretory capacity after human islet transplantation according to the CIT07 protocol. Diabetes. 2013; 62: 2890–2897.
73. Johannesson B et al. Toward beta cell replacement for diabetes. The EMBO Journal. 2015; 34 (7): 841–855.
74. Meier RPH, Andrey DO, Sun P et al. Pancreas preservation fluid microbial contamination is associated with poor islet isolation outcomes – a multi-centre cohort study. Transpl Int. 2018.
75. Desai CS, Khalid KM, Ma X et al. Effect of liver histopathology on islet cell engraftment in the model mimicking autologous islet cell transplantation. Islets. 2017; 9 (6): 140–149.
76. Wilson GC, Sutton JM, Salehi M et al. Surgical outcomes after total pancreatectomy and islet cell autotransplantation in pediatric patients. Surgery. 2013; 154: 777–783.
77. Ahmad SA, Lowy AM, Wray CJ et al. Factors associated with insulin and narcotic independence after islet autotransplantation in patients with severe chronic pancreatitis. J Am Coll Surg. 2005; 201: 680–687.
78. Solomina J, Golebiewska J, Kijeka MR et al. Pain control, glucose control, and quality of life in patients with chronic pancreatitis after total pancreatectomy with islet autotransplantation: a preliminary report. Transplantation Proceedings. 2017; 49: 2333–2339.
Рецензия
Для цитирования:
Загайнов В.Е., Мелешина А.В., Корнева К.Г., Васенин С.А., Загайнова Е.В. Трансплантационные технологии для лечения нарушений углеводного обмена. Вестник трансплантологии и искусственных органов. 2020;22(1):184-195. https://doi.org/10.15825/1995-1191-2020-1-184-195
For citation:
Zagainov V.Е., Meleshina A.V., Korneva К.G., Vasenin S.А., Zagaynova E.V. Transplantation technologies for treatment of carbohydrate metabolism disorders. Russian Journal of Transplantology and Artificial Organs. 2020;22(1):184-195. https://doi.org/10.15825/1995-1191-2020-1-184-195
Просмотров: 711
Послать статью по эл. почте 